The M2T™ program is a recombinant protein-based immunotherapy platform that delivers antigens directly to MHCII molecules on antigen-presenting cells. This boosts presentation to the immune system, overcomes immune tolerance, and generates a powerful B and T cell response against the chosen antigen. LTI-214 (M2T-CD33) is our lead clinical candidate for first-in-man studies in Acute Myelogenous Leukemia (AML) and other hematology/oncology indications. LTI-002 (M2T-mesothelin) is our second development candidate for pancreatic cancer. In addition, we are developing other candidates for some of the deadliest cancers, which are in need of new and effective therapies.
Pipeline
Mobilizing and directing immune cells in the fight against cancer.
